The estimated Net Worth of William J. Regan is at least $173 dollars as of 29 June 2017. Mr Regan owns over 20,000 units of Navidea Biopharmaceuticals Inc stock worth over $173 and over the last 12 years he sold NAVB stock worth over $0.
Mr has made over 3 trades of the Navidea Biopharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of NAVB stock worth $10,600 on 29 June 2017.
The largest trade he's ever made was buying 20,000 units of Navidea Biopharmaceuticals Inc stock on 29 June 2017 worth over $10,600. On average, Mr trades about 2,308 units every 121 days since 2013. As of 29 June 2017 he still owns at least 172,977 units of Navidea Biopharmaceuticals Inc stock.
You can see the complete history of Mr Regan stock trades at the bottom of the page.
William J. Regan is the Chief Strategy Officer & Chief Compliance Officer at Navidea Biopharmaceuticals Inc.
Mr Regan is 69, he's been the Chief Strategy Officer & Chief Compliance Officer of Navidea Biopharmaceuticals Inc since . There are no older and 7 younger executives at Navidea Biopharmaceuticals Inc.
William's mailing address filed with the SEC is 5600 BLAZER PARKWAY, SUITE 200, , DUBLIN, OH, US 43017.
Over the last 13 years, insiders at Navidea Biopharmaceuticals Inc have traded over $3,167,813 worth of Navidea Biopharmaceuticals Inc stock and bought 7,718,496 units worth $6,241,151 . The most active insiders traders include John K Jr. Scott, Perry A Karsen, and Life Sciences, Llc Platinum.... On average, Navidea Biopharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $159. The most recent stock trade was executed by John K Jr. Scott on 10 April 2022, trading 3,260 units of NAVB stock currently worth $3.
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Navidea Biopharmaceuticals Inc executives and other stock owners filed with the SEC include: